• Mutation; HGNC; HGNC:644; AR; Simple; p.His875Tyr (c.2623C>T); ClinVar=VCV000009834; Zygosity=Hemizygous (PubMed=11306464).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=14518029).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Unspecified (PubMed=14518029).
  

PubMed=11306464
Gregory C.W., Johnson R.T. Jr., Mohler J.L., French F.S., Wilson E.M.
Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.
Cancer Res. 61:2892-2898(2001)

PubMed=14518029; DOI=10.1002/pros.10290
van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.
Molecular characterization of human prostate carcinoma cell lines.
Prostate 57:205-225(2003)

PubMed=14518030; DOI=10.1002/pros.10291
van Bokhoven A., Caires A., Di Maria M., Schulte A.P., Lucia M.S., Nordeen S.K., Miller G.J., Varella-Garcia M.
Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines.
Prostate 57:226-244(2003)

CLPUB00698
van Bokhoven A.
Models for prostate cancer. Molecular characterization and critical appraisal of human prostate carcinoma cell lines.
Thesis PhD (2004); Katholieke Universiteit Nijmegen; Nijmegen; Netherlands

PubMed=23117885; DOI=10.1158/0008-5472.CAN-12-3630; PMCID=PMC3549016
Li Y.-M., Chan S.-C., Brand L.J., Hwang T.H., Silverstein K.A.T., Dehm S.M.
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Cancer Res. 73:483-489(2013)

PubMed=27036029; DOI=10.18632/oncotarget.8456; PMCID=PMC5041979
Kregel S., Chen J.L., Tom W., Krishnan V., Kach J., Brechka H., Fessenden T.B., Isikbay M., Paner G.P., Szmulewitz R.Z., Vander Griend D.J.
Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Oncotarget 7:26259-26274(2016)

PubMed=27271795; DOI=10.1002/pros.23190
Shourideh M., DePriest A., Mohler J.L., Wilson E.M., Koochekpour S.
Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line.
Prostate 76:1067-1077(2016)

PubMed=29194687; DOI=10.1002/pros.23459; PMCID=PMC5768451
Fiandalo M.V., Wilton J.H., Mantione K.M., Wrzosek C., Attwood K.M., Wu Y., Mohler J.L.
Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.
Prostate 78:213-221(2018)